Barclays’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Barclays’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4	Closed	-$51	–	5476
2022 Q4	$51	Hold	4	–	–	﹤0.01%	5213
2022 Q3	$0	Hold	4	–	–	﹤0.01%	5258
2022 Q2	$0	Sell	4 -41	-91%	-$3.51K	﹤0.01%	5396
2022 Q1	$7K	Buy	+45	New	+$10.4K	﹤0.01%	4661

Other funds holding FNCH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AMC

Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Barclays's FNCH Position: Q1 2023 in Review

Barclays sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q1 2023, closing a stake of 4 shares — an estimated $51 sold.

Barclays first reported a position in FNCH in Q1 2022 and held it in 4 quarters. The position peaked at $7K in Q1 2022. 33 funds tracked by Wall St. Rank hold FNCH as of Q1 2023.

Barclays reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Barclays sold 4 Finch Therapeutics Group, Inc. Common Stock shares in Q1 2023, an estimated $51.
Barclays first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
Barclays's Finch Therapeutics Group, Inc. Common Stock position peaked at $7K in Q1 2022.
33 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q1 2023.

Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.